"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics
- PMID: 17709549
- DOI: 10.4049/jimmunol.179.5.3325
"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics
Abstract
The CD28-specific mAb TGN1412 rapidly caused a life-threatening "cytokine storm" in all six healthy volunteers in the Phase I clinical trial of this superagonist, signaling a failure of preclinical safety testing. We report novel in vitro procedures in which TGN1412, immobilized in various ways, is presented to human white blood cells in a manner that stimulates the striking release of cytokines and profound lymphocyte proliferation that occurred in vivo in humans. The novel procedures would have predicted the toxicity of this superagonist and are now being applied to emerging immunotherapeutics and to other therapeutics that have the potential to act upon the immune system. Data from these novel procedures, along with data from in vitro and in vivo studies in nonhuman primates, suggest that the dose of TGN1412 given to human volunteers was close to the maximum immunostimulatory dose and that TGN1412 is not a superagonist in nonhuman primates.
Similar articles
-
After TGN1412: recent developments in cytokine release assays.J Immunotoxicol. 2013 Jan-Mar;10(1):75-82. doi: 10.3109/1547691X.2012.711783. Epub 2012 Sep 11. J Immunotoxicol. 2013. PMID: 22967038 Free PMC article.
-
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.Br J Pharmacol. 2010 Oct;161(3):512-26. doi: 10.1111/j.1476-5381.2010.00922.x. Br J Pharmacol. 2010. PMID: 20880392 Free PMC article.
-
Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.J Immunol Methods. 2015 Sep;424:43-52. doi: 10.1016/j.jim.2015.04.020. Epub 2015 May 7. J Immunol Methods. 2015. PMID: 25960173 Free PMC article.
-
Safety of biologics, lessons learnt from TGN1412.Curr Opin Biotechnol. 2009 Dec;20(6):673-7. doi: 10.1016/j.copbio.2009.10.002. Epub 2009 Nov 4. Curr Opin Biotechnol. 2009. PMID: 19892543 Review.
-
The safety and side effects of monoclonal antibodies.Nat Rev Drug Discov. 2010 Apr;9(4):325-38. doi: 10.1038/nrd3003. Epub 2010 Mar 22. Nat Rev Drug Discov. 2010. PMID: 20305665 Review.
Cited by
-
After TGN1412: recent developments in cytokine release assays.J Immunotoxicol. 2013 Jan-Mar;10(1):75-82. doi: 10.3109/1547691X.2012.711783. Epub 2012 Sep 11. J Immunotoxicol. 2013. PMID: 22967038 Free PMC article.
-
Immune-related adverse events of antibody-based biological medicines in cancer therapy.J Cell Mol Med. 2024 Jul;28(13):e18470. doi: 10.1111/jcmm.18470. J Cell Mol Med. 2024. PMID: 38963257 Free PMC article. Review.
-
A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.Vaccine. 2009 Dec 11;28(2):512-22. doi: 10.1016/j.vaccine.2009.09.127. Epub 2009 Oct 29. Vaccine. 2009. PMID: 19836479 Free PMC article.
-
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.Nat Biotechnol. 2009 Aug;27(8):767-71. doi: 10.1038/nbt.1553. Epub 2009 Jul 20. Nat Biotechnol. 2009. PMID: 19620983
-
Concise review: the relevance of human stem cell-derived organoid models for epithelial translational medicine.Stem Cells. 2013 Mar;31(3):417-22. doi: 10.1002/stem.1290. Stem Cells. 2013. PMID: 23203919 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
